Estimating the direct Disability-Adjusted Life Years (DALYs) associated with SARS-CoV-2 (COVID-19) in the Republic of Ireland: The first full year

Declan Moran ^{*1}, Sara Montero Pires ², Grant Wyper ³, Brecht Devleesschauwer ^{4, 5}, Sarah Cuschieri ⁶, Zubair Kabir ¹.

1. School of Public Health, University College Cork, Cork, Ireland.
2. National Food Institute, Technical University of Denmark, Lyngby, Denmark.
3. Place and Wellbeing Directorate, Public Health Scotland, Glasgow, Scotland.
4. Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
5. Department of Translational Physiology, Infectiology and Public Health, Ghent University, Merelbeke, Belgium
6. Faculty of Medicine & Surgery, University of Malta, Msida, MSD 2080, Malta.

* Corresponding author: E-Mail: 120111161@umail.ucc.ie

Abstract

Objectives

Burden of Disease frameworks facilitate estimation of the health impact of diseases to be translated into a single measure, such as the Disability-Adjusted-Life-Year (DALY).

Methods

DALYs were calculated as the sum of Years of Life Lost (YLL) and Years Lived with Disability (YLD) directly associated with COVID-19 in the Republic of Ireland (RoI) from March 01, 2020, to February 28, 2021. Life expectancy is based on the Global Burden of Disease (GBD) Study life tables for 2019.

Results

There were 220,273 confirmed cases with a total of 4,500 deaths as a direct result of COVID-19. DALYs were estimated to be 51,532.1 (95% Uncertainty Intervals [UI] 50,671.6, 52,294.3). Overall, YLL contributed to 98.7% of the DALYs. Of total symptomatic cases, 6.5% required hospitalisation and of those hospitalised 10.8% required intensive care unit treatment. COVID-19 was likely to be the second highest cause of death over our study's duration.

Conclusion

Estimating the burden of a disease at national level is useful for comparing its impact with other diseases in the population and across populations. This work sets out to standardise a COVID-19 BoD methodology framework for the RoI and comparable nations in the EU.

Introduction

By the beginning of March 2020, cases of COVID-19 had been confirmed in most regions throughout the world (1) with the Republic of Ireland (RoI) being no exception. (2) On March 11, 2020, the WHO, declared COVID-19 a pandemic. (3) On March 12, 2020, the Irish government under advice from the National Public Health Emergency Team (NPHE) closed all educational, childcare, and cultural facilities. This initial response was extended to a full lockdown with a stay-at-home order by March 27, 2020. (4) From this date forward Ireland has been living under varying levels of lockdown as the country continues to fight the COVID-19 pandemic. The Department of Health (DoH) in their February 28, 2021, briefing noted that almost all sectors and communities experienced loss and had been “*tested in ways unimaginable to us this time last year*”. (5)

Internationally there has been a wide disparity relating to the direct impact on population health when considering COVID-19. (1) One option to standardise comparisons between countries is to quantify the combined impact of COVID-19's morbidity and mortality. Burden of Disease (BoD) frameworks facilitate estimation of the health impact of diseases to be translated into a single measure, such as the Disability-Adjusted-Life-Year (DALY). DALYs achieve this through standardising the effects of morbidity and mortality on population health loss as a function of time. The DALY is a health gap metric which measures the healthy life years lost due to diseases, injuries, or risk factors. The DALY is also one of the most internationally used summary measures of population health and is a key metric in the Global Burden of Disease study (GBD). (6) Additionally, the DALY facilitates the comparison of the direct impact of a disease (i.e., COVID-19) against other causes of disease and injury, whilst also facilitating comparison of localised regions or specified demographic groups. (6)

Furthermore, while public conversation on COVID-19 has mainly been centred around those with severe or fatal illness, recent studies highlight an increasing number of people with initially mild COVID-19 who progress to experience prolonged symptoms of which the profile and timeline remains uncertain. Relatively little is known about this “*Long-COVID*”, however, the literature continues to expand. Long-COVID will impact morbidity measures in ongoing and future BoD studies. (7)

Taken together, we set out to estimate the BoD as a direct result of COVID-19 in the RoI from March 01, 2020; to February 28, 2021 (inclusive) using the incidence based internationally comparable metric of DALY.

Methods

Data collection

Data relating to COVID-19 in RoI is publicly available through several bodies. Data in this study was sourced from the DATA.GOV.IE website, which collates data from several national organisations, namely the Central Statistics Office (CSO), the Health Protection Surveillance Centre (HPSC), the Health Service Executive (HSE), the Department of Health and the Open Data Unit of the Department of Public Expenditure and Reform (DPER). The data are publicly available.

Years of Life Lost (YLL)

YLL is the product of the number of deaths (M) and the average remaining life expectancy (RLE) at the time of death: $YLL = M \times RLE$ (6)

COVID-19 case definitions in RoI have been routinely updated during the pandemic in accordance with the European Centre for Disease Prevention and Control (ECDC) guidance and updates. (8) Mortality data independently stratified by sex and age-group for the required period was

published by the CSO on 10 March 2021 for events created on the Computerised Infectious Disease Reporting (CIDR) system up to midnight Friday 05 March 2021. (9) To exclude data from 01 March 2021 to 05 March 2021 and to allow for mortality reclassification, the DoH daily briefings were reviewed up to and including 31 March 2021. To complete the sex data, the sex ratio from the defined data was applied to the “unknown” cases. To complete the age-group data the age-group ratio from the defined data was applied to the “unknown” cases. Finally, the formulated sex ratio was applied to each age-group.

GBD standard life tables for 2019 were used to calculate remaining life expectancy (RLE) for each sex separately. (10) The average RLE was calculated for each age-group by assuming that the average age of death was the midpoint in each age-group, except for the 80+ category where the average age of death was assumed as the average age of persons in the 80+ category recorded in the Irish Life Tables. (11) Population data was taken from the CSO’s most recent Population and Migration Estimates which were calculated for April 2020. (12)

Years Lived with Disability (YLD)

YLD was defined as the product of the number of incident cases (N), the average duration until recovery or death (D), and the disability weight (DW), which is reflective of the reduction in one’s health (measured on a scale from 0 (no impact on full health) to 1 (death)): $YLD_{inc} = N \times D \times DW$ (6)

YLD in this study included 5 health states: asymptomatic, moderate, severe, critical, and post-acute consequences (PAC). Several assumptions were made in relation to informing a person’s categorisation into one of these health states, as seen in Table 1. Polymerase Chain Reaction (PCR) testing criteria for the general public in RoI continues to be based on persons presenting with at least one symptom (being symptomatic), (13) therefore, asymptomatic in this study was defined as a person infected with COVID-19 who did not present for PCR testing; however, this did not account for infections discovered during screening programmes. Asymptomatic cases carried no value for YLD estimation. As described by the European Burden of Disease Network/ECDC consensus disease model, these health states, their description, and their disability weights are based on those from the GBD 2019 study for infectious diseases of the lower respiratory tract, except for those requiring intensive care (Critical), which was defined by the European Disability Weight study. (6, 14) (See table 1)

Table 1: Health state categorisation, disability weights and durations (days).

[Burden of disease of COVID-19: Protocol for Country Studies, Brussels, 2020], [Burden of Disease Methods: A Guide to Calculate COVID-19 Disability-Adjusted Life Years. Brussels, 2021]

Health state	Assumption/Description	Disability weight (95% uncertainty interval)	Duration
Asymptomatic	Person was infected with COVID-19 but did not present for a Polymerase Chain Reaction (PCR) confirmation test.	Nil	0.00
Moderate	Person had a PCR confirmed COVID-19 diagnoses which was managed in the community and did not require hospitalisation.	0.051 (0.032 – 0.074)	7.79
Severe	Person had a PCR confirmed COVID-19 diagnoses which required hospitalisation but <u>not</u> intensive care.	0.133 (0.088 – 0.190)	10.9
Critical	Person had a PCR confirmed COVID-19 diagnoses which required hospitalisation and admission to intensive care (with or	0.655 (0.579 – 0.727)	13.1

without ventilation).			
Post-Acute Consequences	Person infected with COVID-19 developed chronic sequelae (note persons attributed to the “ <i>post-acute consequences</i> ” health state did not necessarily have a PCR confirmed COVID-19 diagnoses).	0.219 (0.148 – 0.308)	28

Morbidity data for all health states, independently stratified by sex and age-group for the required period remains openly available on data.gov.ie (15), except for the health state “*asymptomatic*”, which was assumed to have a 3:1 ratio based on seroprevalence studies. (16, 17) Additionally, the transition probability for the health state “*PAC*” was assumed to be 13.3% of the overall symptomatic incidence with a duration of 28 days. (18) For estimated mean duration relating to health state “*moderate*”, the mean duration for lower respiratory tract infections from the GBD 2019 study was used. (14) Estimated mean duration for health states “*severe*” and “*critical*” were provided by a recent study based on Irish hospital data. (19) Similar to YLL estimates above, a formulated sex ratio was applied to each age-group.

Disability Adjusted Life Years (DALY)

DALYs are calculated simply by summing the YLLs and YLDs (DALY = YLL + YLD).

Ethical considerations

Ethical approval for this study was obtained from the Social Research Ethics Committee of University College Cork (UCC).

Analyses

As DALYs are a unit of time based on person-years, our results are scaled by a factor of $\frac{1}{365.25}$, this reflects the contribution of individual days to a complete year. For ease of comparison with previous studies the YLLs, YLDs and DALYs were also estimated per 100,000 population. The uncertainty intervals (UI) from the GBD 2019 life tables were used to estimate the upper and lower intervals of the YLL. The respective disability weight UIs from the GBD 2019 study for infectious diseases of the lower respiratory tract and the European Disability Weight study were used to estimate the upper and lower intervals of the YLD, these UI were subsequently used to estimate the upper and lower estimates of the DALY. Uncertainties were present in our analyses, particularly in relation to the estimation of the proportion of cases who transitioned to health state “*PAC*” and also the duration of health state “*PAC*”. A sensitivity analysis assessed the effect of a 5% and 25% transition probability of symptomatic cases to “*PAC*”. We also assessed “*PAC*” durations of 14 and 56 days. Additionally, a combination of assumptions relating to “*PAC*” were applied to minimise and maximise the YLD. For minimisation we halved the transition probability and the duration of “*PAC*”. For maximisation we doubled the transition probability to “*PAC*”, also applying this to asymptomatic cases and doubled the duration of “*PAC*”. (See table 6).

Results

Overall findings

There were 220,273 PCR confirmed cases of COVID-19 with a total of 4,500 deaths (confirmed or probable) as a direct result of COVID-19 within the studies stated parameters. The incidence numbers for each health state are seen in Table 2.

A fatality rate of 0.49% was estimated when considering all infected persons (asymptomatic + symptomatic). Of symptomatic cases only, we estimate a fatality rate of 2.0% and a hospitalisation rate of 6.5%. Of those hospitalised, 10.8% required treatment in an intensive care unit (ICU).

Table 2: Incidence by health state.

Name	Data input proxy	Incidence
Asymptomatic	Estimate of suspected asymptomatic cases	660819
Moderate	Confirmed case managed in the community	205991
Severe	Confirmed case requiring hospital admission (non-ICU)	12891
Critical	Confirmed case requiring ICU admission	1391
Post-Acute Consequences	Transition probabilities from cases to post-acute consequences	29296

Years of Life Lost (YLL)

The sex of each case was defined for 4,154 cases and was “unknown” for 346 cases. Age-group was defined for 4,149 cases and was “unknown” for 351 cases. We estimate YLL of 50,858 (50,220.4, 51,344.8) (males: 24,999.4 (24,652.5, 25,181.3); females: 25,858.6 (25,567.9, 26,163.5)). Based on age, persons in the 65-79 age-groups had the highest YLL at 21,103.9 (20,839.7, 21,368.1) (males: 10,467 (10,326.5, 10,607.5); females: 10,636.9 (10,513.2, 10,760.6)). The highest number of deaths by sex and age-group was seen in males 80+ (1,507, 2143.7 deaths per 100,000 persons). The average age of death was 79 (males: 78.8; females: 79.2). (See table 3).

Table 3: Years of life lost by sex and age-group

Males	Deaths	YLL	YLL (100,000)
0-14	0	0	0
15-24	0	0	0
25-44	22	1,014.9 (1,008.3, 1,023.7)	148
45-64	163	4469.3 (4420.3, 4501.9)	735.5
65-79	702	10467 (10326.5, 10607.5)	3,895.6

80+	1507	9048.2 (8897.4, 9048.2)	12,862
Total	2394	24,999.4 (24,652.5, 25,181.3)	1,013.2
Females	Deaths	YLL	YLL (100,000)
0-14	0	0	0
15-24	0	0	0
25-44	19	939.2 (933.5, 944.9)	132
45-64	143	4,994.1 (4,965.5, 5,037)	806.3
65-79	618	10,636.9 (10,513.2, 10,760.6)	3,785.5
80+	1326	9,288.4 (9155.7, 9,421)	9,226.6
Total	2106	25,858.6 (25,567.9, 26,163.5)	1,028.7

Years Lived with Disability (YLD)

Sex was defined in 219,507 cases and was “unknown” in 766 cases. Age-group was defined for 219,466 cases and was “unknown” in 807 cases. We estimate YLD of 674.2 (95% UI 451.1, 949.5). Males constituted YLD of 316.9 (212, 446.3) and females 357.4 (239.1, 503.2). The largest contributing age-group was “25-44” with YLD of 229.2 (153.4, 322.8) and the largest contributing health state is “PAC” with YLD of 369.1 (249.5, 519.2). The largest contributing combined sub-population (sex, age-group, and health state) were “females” “25-44” “PAC” with YLD of 66.5 (45, 93.6), this population consisted of 5,279 persons. (See table 4).

Table 4: Years lived with disease estimates

YLD by health state	
Health State	YLD
Asymptomatic	0
Moderate	220.8 (138.5, 320.3)
Severe	51.5 (34.1, 73.5)
Critical	32.8 (29.0, 36.5)
Post-Acute Cons.	369.1 (249.5, 519.2)
Total	674.2 (451.1, 949.5)

YLD by sex and health state			
	Health State	Incidence	YLD
Males	Moderate	96,816	103.8 (65.1, 150.6)
	Severe	6,059	24.2 (16.0, 34.6)
	Critical	654	15.4 (13.6, 17.1)
	PAC	10,353	173.5 (117.3, 244)
Females	Moderate	109,177	117 (73.4, 169.8)
	Severe	6,832	27.3 (18.1, 39)
	Critical	737	17.4 (15.4, 19.3)
	PAC	11,674	195.6 (132.2, 275.2)
YLD by sex and age-group			
	Age-Group	Incidence	YLD
Males	0-14	10,249	28.5 (19.1, 40.2)
	15-24	20,499	57 (38.2, 80.3)
	25-44	38,720	107.7 (72.1, 151.7)
	45-64	29,609	82.4 (55.1, 116)
	65-79	9,110	25.4 (17, 35.7)
	80+	5,694	15.8 (10.6, 22.3)
Females	0-14	11,558	32.1 (21.5, 45.3)
	15-24	23,115	64.3 (43, 90.6)
	25-44	43,663	121.5 (81.3, 171.1)
	45-64	33,389	92.9 (62.2, 130.8)
	65-79	10,274	28.6 (19.1, 40.3)
	80+	6,421	17.9 (12, 25.2)

Disability Adjusted Life Years (DALYs)

We estimated that COVID-19 caused 51,532.1 DALYs (50,671.6, 52,294.3) in the full year period. Overall, YLL contributed 98.7% towards the DALYs with the remaining 1.3% attributed to YLD. The sub-population with highest DALYs were “*Females*” “65-79” with DALYs of 10,665.5 (10,532.3, 10,800.9), which translates to 3,798.3 (3,750.8, 3,846.5) DALYs per 100,000 persons. However, the largest DALYs per 100,000 persons was seen in the Male 80+ population with a total of 12,893.3 (12,671.4, 12,902.6). We estimated 11.5 (11.3, 11.6) DALYs per death. (See table 5), (See table 6).

Table 5: Disability adjusted life years by sex and age-group

Age	Males		Females		Total Persons DALYs
	DALYs	DALYs (per100,000)	DALYs	DALYs (per100,000)	
0-14	28.5 (19.1, 40.2)	5.5 (3.7, 7.8)	32.1 (21.5, 45.3)	6.6 (4.4, 9.3)	60.6 (40.6, 85.5)
15-24	57 (38.2, 80.3)	17.8 (11.9, 25)	64.3 (43, 90.6)	20.7 (13.8, 29.2)	121.3 (81.2, 170.9)
25-44	1,122.6 (1,080.4, 1,175.4)	163.9 (157.7, 171.6)	1,060.7 (1,014.8, 1,116)	149.1 (142.7, 156.9)	2,183.3 (2,095.2, 2,291.4)
45-64	4,551.7 (4,475.4, 4,617.9)	749.6 (737.1, 760.5)	5,087 (5,027.7, 5,167.8)	821.8 (812.2, 834.9)	9,638.7 (9,503.1, 9,785.7)
65-79	10,492.4 (10,343.5, 10,643.2)	3,907.8 (3,852.3, 3,963.9)	10,665.5 (10,532.3, 10,800.9)	3,798.3 (3,750.8, 3,846.5)	21,157.9 (20,875.8, 21,444.1)
80+	9,064 (8,908, 9,070.5)	9,064 (8,908, 9,070.5)	9,306.3 (9,167.7, 9,446.2)	9,250.8 (9,113, 9,389.9)	18,370.3 (18,075.7, 18,516.7)

Table 6: Results of sensitivity & scenario analysis

Description	YLD	DALY
Health state "PAC" transition probability 5%	444.1 (294.6, 641.3)	51,302 (50,515, 51,986.1)
Health state "PAC" transition probability 25%	999.3 (669.8, 1,422.2)	51,857.2 (50,890.2, 52,767)
Health state "PAC" duration 14 days	549.5 (365.8, 789.4)	51,407.4 (50,586.2, 52,134.2)
Health state "PAC" duration 56 days	1,287.8 (864.8, 1,827.9)	52,145.7 (51,085.2, 53,172.7)
Scenario to minimise impact of YLD	424 (282.1, 597.6)	51,281.9 (50,502.5, 51,942.4)
- "PAC" transition probability of 6.65%, symptomatic cases only		
- "PAC" duration of 14 days		
Scenario to maximise impact of YLD	8,157.9 (5,508.6, 11,474.5)	59,015.8 (55,728.92, 62,819.3)
- "PAC" transition probability of 26.6%, asymptomatic and symptomatic cases		
- "PAC" duration of 56 days		

Discussion

This study estimated the BoD as a direct result of COVID-19 in the RoI from March 01, 2020; to February 28, 2021 (inclusive) using the incidence-based internationally comparable metric of the DALY. Overall, there were 220,273 PCR confirmed cases with 4,500 deaths (confirmed or probable), and 51,532.1 (95%UI 50671.6, 52294.3) DALYs. The largest impact on population health was a result of premature mortality with YLL representing 98.7% of the DALYs. We estimated 11.3 YLL per death. This is similar to findings in South Korea and the United States with YLL per death of 9.46 and 9.23 respectively, (20, 21) however, other national BoD studies indicated YLL per death ranging from 4.79 to 15.79. (22, 23) Variation in YLL per death across studies is influenced by which life valuation table is applied. Despite extensive population health interventions designed specifically to reduce the risk of COVID-19, deaths directly related to the virus are likely to rank second when compared to RoI 2019 mortality data. The overall DALYs were marginally higher in males than females; this result was also found in a recent United States study. (21) The largest contributing sub-population were females aged 65-79, however, while the largest DALYs per 100,000 persons were in the male 80+ population. DALY contribution significantly increased in populations 65+. This biological inequality suggests that the higher age-groups of both male and female are at a higher risk, particularly of mortality from COVID-19. The results from sensitivity and scenario analyses highlighted that variation in relation to assumptions relating to YLD input variables have minor impact on the overall DALY estimates as YLD contribute a small percentage of the total DALYs.

The DALY metric is a useful health gap summary measure when attempting to identify the impact of a disease on public health. This study adopted the incidence approach for estimating DALYs as incidence data was widely reported.

As the natural history of COVID-19 is evolving, at the time of completion of this study there is no longitudinal data available. DALY estimates for COVID-19 burden are available to a limited number of countries using data over varying time durations. Early on in the pandemic, both South Korea estimated DALYs based on approximately 3-month durations, 2,531 and 121,449 DALYs respectively. (20, 22) Studies of approximately 1 year duration completed in Germany, Scotland, and Malta estimate DALYs of 305,641, 96,519 and 5,478 respectively. (24, 25, 23)

Contextualisation

For contextualisation, we compared this study's findings with RoI GBD data for 2019. (26) COVID-19 is likely to be the second highest cause of death in the RoI over our study's duration, with only ischemic heart disease (IHD) causing more deaths. Due to mortality being such a high contributing factor to the DALYs, COVID-19 is also likely to have the second highest YLL. Additionally, our COVID-19 DALY estimates are comparable in magnitude to estimates due to 'Unintentional Injuries' (54,835.6) and 'Communicable, Maternal, Neonatal, and Nutritional Diseases' (48,853.6), while our YLD estimates are comparable in magnitude to Non-Hodgkin Lymphoma (682.0) and Idiopathic Developmental Intellectual Disability (642.5) estimates.

Methodological challenges

There were several methodological challenges observed in this study. Publicly available data was identified through the CSO and the HPSC; however, no data was publicly available collated by sex and age, nor was it available compiled specifically for this study's date range. To overcome these issues, some necessary assumptions were made. Where data were recorded as "Unknown" (i.e., sex), the ratio from the defined data was applied to the "unknown" data. Age of death was taken as the midpoint in each age category except for the 80+ category where the average age of death was assumed as the average age of persons in that category as per Irish life tables. Privacy restrictions mean that publicly available mortality data with sub-population counts of <5 (i.e., *males 0- 14*) remain unavailable, therefore this study's YLL estimations are applicable only for those aged 24 and above;

this in turn will result in DALY underestimation. We estimated a maximum underestimation of 1,118.0 (95%UI 1,113.1, 1,123.2) DALYs. To allow for mortality reclassification, the Department of Health daily briefings were reviewed up to and including 31 March 2021; however, there may have been further reclassification post this date. Despite the above uncertainties, our estimates of COVID-19 mortality are unlikely to significantly differ from the final mortality estimates. Due to the recency and ongoing nature of the COVID-19 pandemic, no attempt was made to account for multimorbidity.

BoD studies use DALYs as a tool to assist international comparability; however, in respect of COVID-19 direct comparability between countries remains difficult as studies may use dissimilar life valuation tables. Additionally, due to existing pre-pandemic vulnerabilities specific to each country's population, the exact same response applied across countries would likely yield differences in DALY estimates. Therefore, comparisons will not be straightforward, as to achieve the same results proportionately, and differences in investment in interventions would be required.

Comparison of COVID-19 cases with 2019 GBD Study is for contextualisation only. Given the age profile, it is implausible that all COVID-19 deaths are additional (i.e., deaths in the higher age-groups may have occurred irrespectively due to other causes). A lack of clarity remains in relation to 'dying from COVID' and 'dying with COVID'. However, case definitions in RoI have been routinely updated during the pandemic in accordance with ECDC guidance and updates. (8)

This study estimates the direct burden relating to COVID-19, and no attempt was made to measure the indirect burden resulting from COVID-19, or the behavioural changes and implemented control measures (i.e., mental health, reduced screening capacity, missed developmental checks etc).

Implications for policy and research

COVID-19 has had a detrimental effect on the health of the Irish population. (27, 5) Despite extensive control measures, COVID-19 is likely to be the second highest cause of death from a single disease in the RoI within this study's duration. It would seem highly likely that the synergistic effects of public health measures implemented during this time period could have had a significant positive population health impact; older adults bore an unequal health burden which ultimately resulted in greater DALYs for this population which were overwhelming informed by YLL. The most obvious strategy for DALY reduction relating to COVID-19 would be to focus on mortality reduction, with particular focus on high-risk groups.

Future research must focus on estimating COVID-19 specific DWs, an extensive BoD study relating to the *indirect* effects of the COVID-19 pandemic, and an extensive study relating to the profile and timeline of "*Long-COVID*".

Conclusion

Similar to comparable nations, the health of the Irish population has been impacted by the COVID-19 pandemic, the older populations bearing an unequal burden, particularly in relation to mortality. This work sets out to develop and adapt a standardised COVID-19 BoD methodology framework for Ireland and other comparable EU nations and beyond.

Acknowledgements

This study was completed in association with the European Burden of Disease Network (burden-EU) which was established in 2019 to function as a technical platform for integrating and strengthening capacity in BoD assessment across Europe and beyond. (6)

References

1. World Health Organisation. WHO Coronavirus (COVID-19) Dashboard [Internet]. Geneva: World Health Organisation; 2021 [updated 2021 June 06th; cited 2021 June 07th]. Available from: <https://covid19.who.int/>
2. Department of Health. Statement from the National Public Health Emergency Team - Saturday 29 February [Internet]. Dublin: Department of Health; 2020 [updated 2020 October 25th; cited 2021 June 07th]. Available from: <https://www.gov.ie/en/press-release/2f75fd-statement-from-the-national-public-health-emergency-team-sat-29-feb/>
3. World Health Organisation. WHO Director General's opening remarks at the media briefing on COVID-19: 2020 March 11 [Internet]. Geneva: World Health Organisation; 2020 [updated 2020 March 11th; cited 2021 June 07th]. Available from: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>
4. Citizens Information. Public health measures for COVID-19 [Internet]. Dublin: Citizens Information; 2020 [update undated; cited 2021 March 01st]. Available from: https://www.citizensinformation.ie/en/health/covid19/public_health_measures_for_covid19.html
5. Department of Health. Latest updates on COVID-19 (Coronavirus) [Internet]. Dublin: Department of Health; 2021 [updated 2021 February 28th; cited 2021 March 01st]. Available from: <https://www.gov.ie/en/news/7e0924-latest-updates-on-covid-19-coronavirus/>
6. European Burden of Disease Network. Burden of disease of COVID-19: Protocol for Country Studies [Internet]. Brussels: European Burden of Disease Network; 2020 [updated unknown; cited 2021 March 01st]. Available from: <https://www.burden-eu.net/docs/covid19-bod-protocol.pdf>
7. H.E. Davis et al., Characterizing long COVID in an international cohort: 7 months of symptoms and their impact, E Clinical Medicine [Internet]. 2021 August 01st [cited 2021 August 08th]; 38(2021):101019. Available from: <https://www.thelancet.com/action/showPdf?pii=S2589-5370%2821%2900299-6>
8. Health Protection Surveillance Centre. Epidemiology of COVID-19 in Ireland FAQs [Internet]. Dublin: Health Protection Surveillance Centre; 2020 [updated unknown; cited 2021 June 15th]. Available from: <https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/epidemiologyfrequentlyaskedquestions/>
9. Central Statistics Office. COVID-19 Deaths and Cases, Series 26 [Internet]. Dublin: Central Statistics Office; 2021 [updated 2021 March 12th; cited 2021 June 13th]. Available from: <https://www.cso.ie/en/releasesandpublications/br/b-cdc/covid-19deathsandcasesseries26/>
10. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Life Tables 1950-2019. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2020 [updated 2020 November 18th; cited 2021 September 28th]. Available from: <http://ghdx.healthdata.org/record/ihme-data/gbd-2019-life-tables-1950-2019>
11. Central Statistics Office. Irish Life Tables No. 17 2015-2017 [Internet]. Dublin: Central Statistics Office; 2020 [updated 2020 July 07th; cited 2021 June 13th]. Available from: <https://www.cso.ie/en/releasesandpublications/er/ilt/irishlifetablesno172015-2017/>

12. Central Statistics Office. Population and Migration Estimates April 2020 [Internet]. Dublin: Central Statistics Office; 2020 [updated 2020 August 20th; cited 2021 June 13th]. Available from: <https://www.cso.ie/en/releasesandpublications/er/pme/populationandmigrationestimatesapril2020/>
13. Health Service Executive. Get a HSE COVID-19 PCR test. [Internet]. Dublin: Health Service Executive; 2021 [updated unknown; cited 2021 November 13th]. Available from: <https://www2.hse.ie/conditions/covid19/testing/get-tested/>
14. Wyper GMA, Assunção RMA, Colzani E, Grant I, Haagsma JA, Lagerweij G, Von der Lippe E, McDonald SA, Pires SM, Porst M, Speybroeck N, Devleesschauwer B. Burden of Disease Methods: A Guide to Calculate COVID-19 Disability-Adjusted Life Years. *Int J Public Health* 2021; 66:619011.
15. Health Protection Surveillance Centre (data.gov.ie). Covid Statistics Profile HPSC Ireland Open Data [Internet]. Dublin: Health Protection Surveillance Centre; 2021 [updated 2021 June 12th; cited 2021 June 13th]. Available from: <https://data.gov.ie/dataset/covidstatisticsprofilehpscirelandopendata1>
16. Health Protection Surveillance Centre. Preliminary report of the results of the Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence study [Internet]. Dublin: Health Protection Surveillance Centre; 2020 [updated undated; cited 2021 June 14th]. Available from: <https://www.hse.ie/scopi>
17. Mahajan, A, Solanki R, Sivadas N. Estimation of undetected symptomatic and asymptomatic cases of COVID-19 infection and prediction of its spread in the USA. *J Med Virol.* 2021; 93:3202–3210.
18. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nat Med.* 2021 April 01; 27(4): 626–631. doi:10.1038/s41591-021-01292-y.
19. Economic & Social Research Institute. Hospital admission probability and length of stay among Covid-19 confirmed cases [Internet]. Dublin: Economic and Social Research Institute; 2021 [updated 2021 February 18th; cited 2021 June 21st]. Available from: <https://www.esri.ie/publications/hospital-admission-probability-and-length-of-stay-among-covid-19-confirmed-cases>
20. Min WJ, Dun SG, Rhieun K, Seung WL, Minsu O, Young EK, In HO, Seok JY, and Hyesook P. The Burden of Disease due to COVID-19 in Korea Using Disability-Adjusted Life Years. *J Korean Med Sci.* 2020; 35(21):e199.
21. Quast T, Andel R, Gregory S, Storch EA. Years of life lost associated with COVID-19 deaths in the United States. *J Public Health.* 2020; 42(4):717-722.
22. Nurchis MC, Pascucci D, Sapienza M, Villani L, D'Ambrosio F, Castrini F, Specchia ML, Laurenti P, and Damiani G. Impact of the Burden of COVID-19 in Italy: Results of Disability-Adjusted Life Years (DALYs) and Productivity Loss. *Int. J. Environ. Res. Public Health* 2020; 17(12):4233

23. Cuschieri S, Calleja N, Devleesschauwer B, Wyper GMA. Estimating the direct COVID-19 disability-adjusted life years impact on the Malta population for the first full year. BMC Public Health. 2021; 21:1827 <https://doi.org/10.1186/s12889-021-11893-4>
24. Rommel A, von der Lippe E, Plass D, Ziese T, Diercke M, an der Heiden M, Haller S, Wengler A, on behalf of the BURDEN 2020 Study Group: The COVID-19 disease burden in Germany in 2020—years of life lost to death and disease over the course of the pandemic. Dtsch Arztebl Int. 2021; 118(Forthcoming).
25. Wyper G, Fletcher E, Grant I, McCartney G, Fischbacher C, Harding O, Jones H, de Haro Moro MT, Speybroeck N, Devleesschauwer B, Stockton DL. Measuring the direct population impact of COVID-19 in Scotland, 2020: estimating disability-adjusted life years (DALYs) during the first full calendar year. (Unpublished).
26. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2020[update undated; cited 2021 August 27th]. Available from: <http://ghdx.healthdata.org/gbd-results-tool>.
27. Economic and Social Research Institute. Quarterly Economic Commentary, autumn 2020 [Internet]. Dublin: Economic and Social Research Institute; 2020 [updated 2020 October 08th; cited 2021 April 13th]. Available from: <https://www.esri.ie/publications/quarterly-economic-commentary-autumn-2020>
28. Central Statistics Office. RMF Application Procedure [Internet]. Dublin: Central Statistics Office; undated; [update undated; cited 2021 August 27th]. Available from: <https://www.cso.ie/en/aboutus/lgdp/csodatapolicies/dataforresearchers/rmfapplicationprocedure/>

Tables & Figures

Table 1:	Health state categorisation, disability weights and durations (days). [Burden of disease of COVID-19: Protocol for Country Studies, Brussels ,2020], [Burden of Disease Methods: A Guide to Calculate COVID-19 Disability-Adjusted Life Years. Brussels, 2021]
Table 2:	Incidence by health state.
Table 3:	Years of life lost by sex and age-group.
Table 4:	Years lived with disability estimates.
Table 5:	Disability adjusted life years by sex and age group.
Table 6:	Result of sensitivity & scenario analysis.

Abbreviations

BoD	Burden of Disease
CIDR	Computerised Infectious Disease Reporting
CSO	Central Statistics Office
DALY	Disability Adjusted Life Year
DoH	Department of Health

DPER	Department of Public Expenditure and Reform
DW	Disability Weight
ECDC	European Centre for Disease Control
GBD	Global Burden of Disease
HPSC	Health Protection Surveillance Centre
HSE	Health Service Executive
ICU	Intensive Care Unit
IHME	Institute for Health Metrics and Evaluation
NPHET	National Public Health Emergency Team
PAC	Post-Acute Consequences
PCR	Polymerase Chain Reaction
RLE	Remaining Life Expectancy
RMF	Research Microdata Files
Rol	Republic of Ireland
UCC	University College Cork
UI	Uncertainty Intervals
YLD	Years Lived with Disability
YLL	Years of Life Lost
WHO	World Health Organisation